Compare USLM & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | EVO |
|---|---|---|
| Founded | 1948 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 568.6M |
| IPO Year | 1994 | 2007 |
| Metric | USLM | EVO |
|---|---|---|
| Price | $111.72 | $1.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.17 |
| AVG Volume (30 Days) | 107.3K | ★ 153.5K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ 23.22 | N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $144,435,000.00 | N/A |
| Revenue This Year | $11.88 | N/A |
| Revenue Next Year | $13.43 | $20.51 |
| P/E Ratio | $49.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $96.27 | $1.50 |
| 52 Week High | $141.44 | $4.27 |
| Indicator | USLM | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.58 | 46.64 |
| Support Level | $102.60 | $1.50 |
| Resistance Level | $114.22 | $1.97 |
| Average True Range (ATR) | 3.02 | 0.05 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 52.24 | 76.00 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. The company supplies its products predominantly to the construction including highway, road, and building contractors, industrial including paper and glass manufacturers, environmental including municipal sanitation and water treatment facilities and flue gas treatment processes, metals including steel producers, oil and gas services, roof shingle manufacturers and agriculture including poultry industries. The company operates through its Lime and Limestone Operations segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.